共 50 条
- [12] Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis BMC Pharmacology and Toxicology, 22
- [13] Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis BMC PHARMACOLOGY & TOXICOLOGY, 2021, 22 (01):
- [17] An Animal Model for the Juvenile Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis PLOS ONE, 2016, 11 (07):
- [19] Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (01):